Related by context. All words. (Click for frequent words.) 64 autologous SCT 64 transplantation HSCT 64 biochemical relapse 63 ASCT 63 metastatic GIST 63 chronic hemodialysis 62 transplantation HCT 62 hepatectomy 62 PSA nadir 62 radioiodine therapy 62 cytoreduction 62 chemoradiation therapy 62 tumor resection 62 renal transplantation 62 metastatic malignant 62 debulking surgery 61 renal transplant 61 elective PCI 61 parathyroidectomy 61 primary percutaneous coronary 61 leukemia AML 61 external beam radiotherapy 61 allogeneic hematopoietic stem cell 61 solid organ transplantation 61 neoadjuvant 61 underwent resection 61 colorectal cancer liver metastases 61 operable breast cancer 61 5-fluorouracil/leucovorin 61 transurethral resection 61 lung resection 61 acute GvHD 60 ribavirin RBV 60 posttransplant 60 severe neutropenia 60 cystectomy 60 thoracoscopic lobectomy 60 relapsed MM 60 Neoadjuvant 60 biochemical recurrence 60 Flu Cy 60 nephrectomy 60 chemoradiotherapy 60 concurrent chemoradiation 60 TACE 60 autologous hematopoietic stem cell 60 diagnosed multiple myeloma 60 FOLFOX4 60 autologous stem cell 60 Surgical resection 60 FOLFIRI alone 60 plus dexamethasone 60 total abdominal hysterectomy 60 metastatic renal cell carcinoma 60 antithymocyte globulin 59 preoperative chemotherapy 59 metastatic malignant melanoma 59 angioplasty stenting 59 fallopian tube carcinoma 59 antithrombotic therapy 59 fibrinolysis 59 autologous transplant 59 partial remissions 59 Mitomycin C 59 radiotherapy RT 59 myelodysplastic myeloproliferative diseases 59 % CI #.#-#.# [003] 59 coronary intervention 59 IV NSCLC 59 stage IIIb IV 59 neoadjuvant treatment 59 radical cystectomy 59 clodronate 59 colectomy 59 XIENCE V PROMUS Stent 59 stem cell engraftment 59 Accelerated Partial Breast Irradiation 59 bypass grafting 59 surgical revascularization 59 liver resection 59 neoadjuvant chemotherapy 59 radical nephrectomy 59 arteriovenous access 59 epithelial ovarian 58 Coronary Artery Bypass Graft 58 pancreatic adenocarcinoma 58 DAPT 58 pancreatic resection 58 CLL SLL 58 total thyroidectomy 58 intravesical therapy 58 IV tPA 58 receiving prophylactic anticoagulation 58 esophagectomy 58 cancer mCRC 58 allogeneic stem cell 58 papillary renal cell carcinoma 58 neoadjuvant therapy 58 anthracycline taxane 58 transarterial chemoembolization 58 stage IIIB 58 placebo dexamethasone 58 locoregional 58 metastatic RCC 58 alfa 2a 58 Postoperative 58 underwent surgical resection 58 aortic root replacement 58 reintervention 58 primary patency 58 CRp 58 CMV disease 58 pulmonary artery banding 58 graft dysfunction 58 myeloablative 58 drug eluting stent implantation 58 adjuvant radiotherapy 58 ribavirin therapy 58 penetrating keratoplasty 58 percutaneous intervention 58 prostatectomy 58 coronary revascularization 58 beam radiotherapy 58 R0 resection 58 pacemaker implantation 58 HBeAg positive patients 58 EBRT 58 thrombocytopenic 58 reimplantation 58 vaginal hysterectomy 58 chlorambucil 58 thrombotic complications 58 invasive aspergillosis 58 transplantation ASCT 58 curative resection 58 leukemia ALL 58 HSCT 58 donor nephrectomy 58 FOLFOX4 alone 57 endothelial keratoplasty 57 prostate carcinoma 57 Solid Tumors RECIST 57 transcatheter aortic valve implantation 57 lymphadenectomy 57 gastrointestinal stromal tumors GIST 57 lenalidomide Revlimid R 57 keratoplasty 57 transthoracic 57 RECIST Response Evaluation Criteria 57 rFVIIa 57 4mg/kg 57 radical prostatectomy RP 57 axillary lymph node 57 tumors GIST 57 renal tumors 57 allogeneic hematopoietic cell 57 5-FU/LV 57 pneumonectomy 57 underwent liver transplantation 57 cisplatin chemotherapy 57 colorectal liver metastases 57 endoscopic resection 57 mRCC 57 hepatic metastases 57 daily subcutaneous injections 57 recombinant FSH 57 adjuvant tamoxifen 57 patients undergoing percutaneous 57 lymphocytosis 57 cytotoxic therapy 57 dose melphalan 57 epoetin alpha 57 azacitidine 57 mCRC patients 57 rFSH 57 Follicular Lymphoma 57 undergoing radical cystectomy 57 Response Evaluation Criteria 57 clinically localized prostate 57 evaluable 57 orchiectomy 57 mitral valve replacement 57 8mg/kg 57 â ‰ ¥ 57 cytoreductive nephrectomy 57 FOLFOX6 57 allogeneic SCT 57 TAXUS Express Stent 57 recurrent glioblastoma multiforme 57 dose dexamethasone 57 pT3 57 localized renal 57 mitomycin C 57 fibrinolytic therapy 57 PegIFN 57 autologous transplants 57 gastrointestinal stromal tumor GIST 57 cytoreductive surgery 57 transarterial 57 chemoradiation 57 revascularisation 57 dasatinib Sprycel ® 57 peginterferon alfa 2a #KD 57 MYLOTARG 57 randomized multicenter trial 57 hemodialysis patients 57 allogeneic transplants 57 percutaneous transluminal coronary angioplasty 57 graft patency 57 partial nephrectomy 57 Gliadel Wafer 57 stent implantation 57 pT2 57 cell lymphoma CTCL 57 FluCAM arm 57 relapsing remitting MS RRMS 57 octreotide LAR 57 abdominal aortic 57 receiving VICTRELIS 56 CR nPR 56 NMIBC 56 resected 56 Allogeneic 56 CHOP chemotherapy 56 lobectomy 56 undetectable HBV DNA 56 segmentectomy 56 lymph node dissection 56 receiving highly emetogenic 56 extubation 56 perioperatively 56 histologically confirmed 56 extracorporeal membrane oxygenation 56 tenecteplase 56 cetuximab Erbitux R 56 atrioventricular block 56 unstable angina pectoris 56 cervical carcinoma 56 metastatic neuroendocrine tumors 56 gastrointestinal stromal tumors 56 refractory acute myeloid 56 remission CR 56 intraperitoneal chemotherapy 56 immunocompetent patients 56 HBeAg seroconversion 56 hepatorenal syndrome 56 allogeneic bone marrow 56 thymectomy 56 TLIF 56 hepatic resection 56 hypogonadal men 56 relapsed multiple myeloma 56 HBeAg negative 56 amoxicillin clavulanate 56 HIPEC 56 polypectomy 56 esophageal resection 56 pelvic lymphadenectomy 56 renal transplants 56 gefitinib Iressa 56 mycophenolate mofetil 56 InterStim Therapy 56 achieved sustained virologic 56 melphalan prednisone 56 TURBT 56 remission induction 56 transurethral 56 Percutaneous Transluminal Coronary Angioplasty 56 evaluable patients 56 interferon ribavirin 56 ß blockers 56 mCi 56 plus prednisone 56 peritoneal dialysis PD 56 abdominal hysterectomy 56 bolus dose 56 JAK2 V#F 56 prostate adenocarcinoma 56 catheter occlusion 56 biliary tract cancer 56 systemic corticosteroids 56 pegylated interferon alfa 56 function DGF 56 5 Fluorouracil 56 adrenalectomy 56 oral Hycamtin 56 docetaxel Taxotere ® 56 Median PFS 56 interstitial brachytherapy 56 achieved ACR# 56 unresectable HCC 56 assessing T DM1 56 monoclonal antibody conjugated 56 orthotopic liver transplantation 56 biologic DMARD 56 intraductal 56 invasive candidiasis 56 Peg IFN 56 recurrent NSCLC 56 intracavitary 56 LEUKINE 56 concomitant antibiotics 56 postoperative AF 56 meniscectomy 56 Aortic valve replacement 56 postoperative atrial fibrillation 56 unstable angina UA 56 artery embolization 56 autologous transplantation 56 alteplase 56 dexamethasone Decadron 56 glycoprotein IIb IIIa inhibitors 56 aneurysms AAA 56 P = .# 56 ABVD 56 deep venous thromboses 56 pancreatic neuroendocrine tumors 56 sirolimus eluting stents 56 undergoing cardiac catheterization 56 cerebral angiography 56 non splenectomized 56 #Gy 56 lung metastases 56 mycophenolate 56 Coronary artery bypass grafting 56 dialysis CKD 56 multiple myeloma MM 56 electrical cardioversion 56 reperfusion therapy 56 transplantation 56 opioid analgesia 56 thrombolytics 56 thoracotomy 56 CCyR 56 refractory chronic myeloid 56 Torisel 56 cardiopulmonary bypass CPB 56 mcg BID 56 steroid refractory 55 radical retropubic prostatectomy 55 Median progression 55 Cystectomy 55 nonischemic 55 carotid artery stenosis 55 artery bypass 55 radiochemotherapy 55 GnRH agonist 55 calcineurin inhibitor 55 Amrubicin 55 ® lenalidomide 55 cGy 55 pretransplant 55 CINTREDEKIN BESUDOTOX 55 adenomatous polyps 55 Bone marrow transplant 55 5FU 55 retransplantation 55 coronary arteriography 55 liver transplant recipients 55 haematologic 55 Decitabine 55 HBsAg 55 ACTEMRA TM 55 refractory chronic lymphocytic 55 stem cell transplantation 55 extrapleural pneumonectomy 55 tamoxifen therapy 55 liver transplantation 55 Degarelix 55 Target Lesion Revascularization TLR 55 syngeneic 55 platinum refractory 55 ara C 55 haematopoietic stem cell 55 chronic GVHD 55 fluorouracil 55 immunosuppression therapy 55 generalized edema 55 bronchoalveolar lavage 55 Resten MP 55 fallopian tube cancers 55 saphenous vein grafts 55 bladder carcinoma 55 colorectal carcinoma 55 chronic thromboembolic pulmonary 55 endometrial carcinoma 55 nicardipine 55 pelvic lymph node dissection 55 HBeAg negative patients 55 generation purine nucleoside 55 prior nephrectomy 55 leiomyomas 55 KRAS mutations occur 55 saline placebo 55 radiofrequency ablation RFA 55 Vidaza azacitidine 55 corticosteroid therapy 55 TAXUS p value 55 thrombocytosis 55 Pegylated Interferon 55 Mitral valve repair 55 bevacizumab Avastin ® 55 Navelbine ® 55 candidemia 55 chemoembolization 55 superficial femoral 55 adjuvant radiation 55 undergoing CABG 55 vasopressor 55 androgen deprivation 55 undergoing coronary artery 55 imipenem 55 recombinant tissue plasminogen 55 binary restenosis 55 revascularization procedure 55 heavily pretreated patients 55 colorectal adenoma 55 MitraClip device 55 resected tumors 55 CsA 55 reintubation 55 occlusive disease 55 Cardiopulmonary bypass 55 eptifibatide 55 tirofiban 55 resectable 55 CABG surgery 55 splenectomized patients 55 refractory NSCLC 55 azacytidine 55 sunitinib malate 55 artificial arteriovenous dialysis 55 Patency 55 pamidronate 55 care regimens CCR 55 recurrent GBM 55 unresectable 55 Operative mortality 55 underwent CABG 55 saphenous vein graft 55 Peginterferon 55 bowel resection 55 Solid Tumors criteria 55 histological subtype 55 mcg kg REBETOL 55 cytogenetic response 55 thyroidectomy 55 postoperative chemotherapy 55 adalimumab Humira 55 ICD therapy 55 immunosuppressive regimen 55 β blockers 55 unresectable tumors 55 estramustine 55 #mg/m# [002] 55 STEMI patients 55 tiuxetan 55 mcg QD 55 LHRH receptor positive 55 euthyroid 55 MYCAMINE 55 RECIST criteria 55 CABG 55 non valvular atrial 55 OPCAB 55 balloon valvuloplasty 55 metoprolol tartrate 55 aneurysm rupture 55 carboplatin paclitaxel 55 SCIg 55 Bezielle 55 transplant HSCT recipients 55 receptor tyrosine kinase inhibitor 55 dacarbazine 55 prostate TURP 55 anticoagulation therapy 55 % CI #.#-#.# [007] 55 relapsed refractory 55 hMG 55 pancreatic islet cell 55 liposomal doxorubicin 55 postoperative morbidity 55 esophagogastric 55 mCi kg 55 de novo kidney transplant 55 metastatic colorectal 55 cinacalcet 55 Naive Patients 55 ovulation induction 55 ischemia driven 55 Resection 55 metastatic adenocarcinoma 55 eosinophilic asthma 55 hemodynamically significant 55 Lenalidomide 55 HoLEP 54 gastrectomy 54 detectable HCV RNA 54 intracoronary 54 clot busting therapy 54 nadolol 54 thrombolytic therapy 54 rt PA 54 cervical lymph nodes 54 acute myeloid 54 cardiogenic shock 54 elevated transaminases 54 Liver transplantation 54 Pegylated Liposomal Doxorubicin 54 normothermic 54 IV bolus 54 reteplase 54 pouchitis 54 urothelial carcinoma 54 thalidomide Thalomid 54 ischemic complications 54 peritoneal carcinomatosis 54 intravenous diuretics 54 BARACLUDE ® 54 gemcitabine cisplatin 54 anagrelide 54 aspartate aminotransferase AST 54 edifoligide 54 #mg/day [002] 54 arteriovenous fistula 54 percutaneous drainage 54 comparator arm 54 intravitreal injection 54 cutaneous T 54 MACCE 54 Dacogen decitabine 54 atypical Hemolytic Uremic Syndrome 54 CMV seropositive 54 interferon therapy 54 NAVISTAR R 54 central venous catheter 54 biventricular 54 jejunal 54 pegylated interferon alpha 54 bolus injection 54 symptomatic paroxysmal AF 54 mechanically ventilated patients 54 recurrent prostate cancer 54 IABP 54 intravenous bolus 54 undetectable HCV RNA 54 inotropic 54 p = NS 54 previously untreated follicular 54 carotid artery stenting 54 adverse cytogenetics 54 Thal Dex 54 renal allograft 54 CD3 monoclonal antibody 54 #mg/m# [001] 54 therapy IMRT 54 peg interferon 54 beta blocker therapy 54 HBeAg + 54 PEG IFN 54 intra articular injection 54 Vascugel 54 stem cell transplants 54 treatment naive genotype 54 endocrine therapies 54 transfemoral 54 Doxil ® 54 crossclamp 54 Adjuvant chemotherapy 54 vapreotide acetate 54 Cetuximab Erbitux 54 MRgFUS 54 telaprevir dosed 54 immunomodulatory therapy 54 pancreatic NET 54 atrial arrhythmias 54 relapsing multiple sclerosis 54 CABG surgeries 54 Pharmacokinetics PK 54 intra arterial 54 bortezomib refractory 54 palliation 54 FIRMAGON 54 idarubicin 54 Multiple Myeloma MM 54 recanalization 54 reinfarction 54 low dose cytarabine 54 anthracyclines taxanes 54 de novo lesions 54 pulmonary resection 54 non squamous NSCLC 54 ovarian stimulation 54 radical prostatectomy 54 renal artery stenting 54 obstructive lesions 54 oral allopurinol 54 polycythemia vera essential thrombocythemia 54 lenalidomide dexamethasone 54 dasatinib Sprycel 54 basiliximab 54 carotid artery stenting CAS 54 imatinib resistant 54 chronic ITP patients 54 gemcitabine Gemzar ® 54 mg m² 54 patients evaluable 54 biologic therapy 54 esophageal candidiasis 54 imatinib therapy 54 tuberous sclerosis TS 54 Secondary endpoints included 54 graft occlusion 54 docetaxel chemotherapy 54 reoperations 54 moderately emetogenic 54 pmol L 54 Kit CD# positive 54 allogeneic HSCT 54 ALT normalization 54 NSTE ACS 54 sacrocolpopexy 54 pegylated interferon alfa 2b 54 SCr 54 virologic failure 54 chemo radiotherapy 54 allogeneic transplantation 54 mg qd 54 coronary artery bypass grafting 54 laparoscopic partial nephrectomy 54 IFN α 54 postmenopausal osteoporotic women 54 mg kg dose 54 pancreatectomy 54 lanthanum carbonate 54 coronary stenting 54 urinary diversion 54 mycophenolate mofetil MMF 54 CIMZIA TM certolizumab pegol 54 Circulating tumor cells 54 balloon brachytherapy 54 incisional 54 sternotomy 54 symptomatic BPH 54 IIIa inhibitors 54 liposomal amphotericin B 54 cyclophosphamide methotrexate 54 reperfusion 54 adriamycin 54 arterial grafts 54 mitoxantrone plus 54 urothelial bladder cancer 54 descending thoracic 54 plus gemcitabine 54 dimeglumine 54 treatment naïve genotype 54 lymphoma CTCL 54 ALND 54 hypofractionated 54 daunorubicin 54 cytogenetic responses 54 virological response 54 Burch colposuspension 54 Nonsurgical 54 Advagraf 54 Arteriovenous 54 herpetic keratitis 54 axillary dissection 54 DSAEK 54 ureteral stones 54 virologic response EVR 54 chronic angina 54 retroperitoneal 54 % Confidence Interval 54 sinus rhythm 54 Trastuzumab 54 ovarian carcinoma 54 hA# 54 dose cytarabine 54 AV fistula 54 hemodiafiltration 54 flutamide 54 contractile muscle 54 DES implantation 54 diagnosed glioblastoma multiforme 54 TEVAR 54 DMARD therapy 54 posttreatment 54 myelodysplastic syndrome MDS 54 VATS lobectomy 54 paracentesis 54 skeletal myoblasts 54 EGFR TKI 54 pulsatile flow 54 relapsing MS 54 ISTODAX ® 54 relapsed refractory multiple myeloma 54 oral rivaroxaban 54 immunosuppressive medication 54 stage IIIb 54 malignant ascites 54 recurrent glioblastoma 54 Impella ® 54 perioperative mortality 54 hereditary antithrombin deficient 54 PSADT 54 Leucovorin 54 aldosterone antagonists 54 laparoscopically assisted 54 unfractionated heparin UFH 54 malignant neoplasm 54 trabeculectomy 54 Myocardial Infarction Study 54 bi ventricular pacing 54 pediatric acute lymphoblastic 54 intravesical 54 Pegasys plus Copegus 54 urethral strictures 54 Zorbtive TM 54 preoperative radiotherapy 54 node dissection 54 CIMZIA TM 54 docetaxel prednisone 54 colon resection 54 operable pancreatic cancer 54 balloon dilation 54 thrombus aspiration 54 nonmetastatic prostate cancer 54 IU ml 54 unresectable recurrent 54 interferon alfa 2a 54 caspofungin 54 progression TTP 54 Irinotecan 54 Median survival 54 iodixanol 54 intralesional 54 lymphocytic leukemia 54 Hepatocellular Carcinoma HCC 54 essential thrombocythemia ET 54 metastatic dermatofibrosarcoma protuberans DFSP 54 valve implantation 54 antimicrobial prophylaxis 54 lung transplantation 54 HBeAg positive 54 chemotherapy docetaxel 54 CIMZIA ™ 54 bilateral oophorectomy 53 Inhaled nitric oxide 53 trabectedin 53 Interagency Registry 53 achieved sustained virological 53 5 fluorouracil leucovorin 53 % CI #.#-#.# [008] 53 galiximab 53 hypervascular tumors 53 APTIVUS r 53 mg/m2 dose 53 doxorubicin cyclophosphamide 53 imatinib Gleevec 53 ertapenem 53 cerebral vasospasm 53 lung esophageal 53 eribulin mesylate 53 stage IIIA 53 coronary bypass graft 53 coil embolization 53 defibrillator implant 53 bypass graft CABG surgery 53 Pericardial 53 evaluable subjects 53 allogeneic transplant 53 osteoporotic compression fractures 53 insulin glulisine 53 Thrombolysis 53 paroxysmal AF 53 recurrent metastatic 53 ischemic cardiomyopathy 53 thalidomide dexamethasone 53 defibrillator implantation 53 noninferior 53 intratumoral 53 hematological parameters 53 resections 53 onset atrial fibrillation 53 micrometastasis 53 oblimersen 53 pCR 53 achieved CCyR 53 RVOT 53 myocardial infarction ventricular fibrillation 53 interferon alfa 2b 53 fludarabine cyclophosphamide 53 portal vein thrombosis 53 kidney transplant recipients 53 Sprague Dawley rats 53 ALT flares 53 median sternotomy 53 PCIs 53 oral anticoagulant therapy 53 systemic hypotension 53 postprocedure 53 immunosuppressant drug 53 percutaneous nephrolithotomy 53 Platinol ® 53 HBeAg 53 GP IIb IIIa inhibitors 53 oral clodronate 53 pre operatively 53 nephron sparing surgery 53 VFEND 53 refractory CLL 53 certolizumab 53 antiangiogenic therapy 53 busulfan 53 LV dysfunction 53 gynecologic surgery 53 cetuximab Erbitux ® 53 HLA matched 53 receiving INTRON 53 MCyR 53 GvHD 53 paclitaxel carboplatin 53 abacavir lamivudine 53 cutaneous melanoma 53 SUVmax 53 sarcomatoid 53 thoracic aortic aneurysms 53 intracerebral hemorrhage ICH 53 photocoagulation 53 preoperative PSA 53 CRRT 53 Hodgkin lymphoma NHL 53 BCG refractory 53 curative therapy 53 functional mitral regurgitation 53 prophylactic treatment 53 Surgical excision 53 percutaneous vertebroplasty 53 revascularization procedures 53 Gleevec resistant 53 Aortic valve 53 asymptomatic carotid stenosis 53 nonmyeloablative 53 neutrophil count 53 atrial ablation 53 duplex ultrasonography 53 bronchogenic carcinoma 53 coronary artery bypass grafts 53 Delayed Graft Function 53 FinESS 53 oral anticoagulation 53 alkylating agent 53 RYGB 53 atherothrombotic events 53 carotid endarterectomy CEA 53 prostate cancer HRPC 53 erlotinib Tarceva ® 53 diameter stenosis 53 aromatase inhibitor therapy 53 allogeneic 53 ER CHOP 53 mg/m2/day 53 thyroid carcinoma 53 orthotopic 53 total parenteral nutrition 53 steroid dexamethasone 53 TEMODAL 53 nonmetastatic 53 induce remission 53 prospectively evaluated 53 mg QD 53 diabetes mellitus DM 53 oral antidiabetic medication 53 CK MB 53 endarterectomy 53 ciclosporin 53 minimally symptomatic 53 prostate cancer mCRPC 53 neurologic progression 53 Cloretazine 53 Postoperative complications 53 ICD implantation 53 piperacillin tazobactam 53 NATRECOR R 53 TURP 53 thoracoscopy 53 -#.# log# 53 stable angina pectoris 53 cardiac dysfunction 53 echocardiographic parameters 53 pancreaticoduodenectomy 53 Events MACE 53 Radiofrequency ablation 53 intracranial hemorrhage ICH 53 Secondary endpoints 53 mL/min/#.# m2 53 etanercept Enbrel 53 vitreoretinal disorders 53 LNG IUS 53 aldosterone antagonist 53 Atypical Hemolytic Uremic Syndrome 53 myocardial revascularization 53 temozolomide Temodar 53 deferoxamine 53 T1a 53 hemodialysis peritoneal dialysis 53 VcMP 53 tissue plasminogen activator tPA 53 prospectively stratified 53 endometrial hyperplasia 53 Restenosis 53 #.#ng/ml 53 transrectal ultrasound guided 53 ug kg 53 exocrine pancreatic insufficiency EPI 53 Radical prostatectomy 53 CR CRu 53 underwent radical prostatectomy 53 cidofovir 53 BoNTA 53 AV grafts 53 dobutamine 53 hematopoietic cell 53 transabdominal 53 Pemetrexed 53 drotrecogin alfa activated 53 locoregional recurrence 53 underwent radical cystectomy 53 appendiceal 53 cytogenic 53 VT VF 53 Index CDAI 53 infarction NSTEMI 53 postoperative pulmonary 53 Acute Myeloid Leukaemia AML 53 endovascular aneurysm repair 53 adalimumab 53 FLT3 ITD 53 Azacitidine 53 uterine fibroid 53 fistula closure 53 malignant neoplasms 53 de novo AML 53 cystoid macular edema 53 specific antigen PSA 53 acute STEMI 53 fluvastatin 53 CALGB # [002] 53 mild renal insufficiency 53 stenting procedure 53 EGFRIs 53 warfarin therapy 53 Degenerative Disc Disease 53 irinotecan chemotherapy 53 valvular disease 53 cranial irradiation 53 Endometrial 53 palliative radiotherapy 53 stage IIIB IV 53 antiarrhythmic drugs 53 ritonavir boosted 53 adjuvant therapy 53 response CCyR 53 surgically resectable 53 angiotensin converting enzyme inhibitor 53 Hormonal therapy 53 rosuvastatin #mg 53 transcranial Doppler ultrasound 53 colorectal metastases 53 thyrotoxicosis 53 KRAS mutant tumors 53 heparin induced thrombocytopenia 53 noninvasive outpatient 53 echocardiographic 53 sustained virological response 53 intravitreal injections 53 myeloid metaplasia 53 #F FDG 53 median PFS 53 gemcitabine Gemzar 53 octreotide 53 lumbar fusion 53 kidney pancreas 53 renal biopsy 53 peginterferon alfa 2a 53 perioperative complications 53 anemia hemoglobin 53 temsirolimus Torisel ® 53 endovenous laser ablation 53 refractory myeloma 53 renal cell carcinomas 53 lipid lowering agents 53 ejection fractions 53 multicenter randomized controlled 53 paraganglioma 53 HCV Genotype 53 refractory AML 53 Acute Coronary Syndromes ACS